Clinician preferences for neurotechnologies in pediatric drug‐resistant epilepsy: A discrete choice experiment
Epilepsia2022Vol. 63(9), pp. 2338–2349
Citations Over TimeTop 12% of 2022 papers
Glory Apantaku, Patrick J. McDonald, Magda Aguiar, Laura Y. Cabrera, Winston Chiong, Mary Connolly, Viorica Hrincu, George M. Ibrahim, K. Julia Kaal, Ashley Lawson, Robert P. Naftel, Éric Racine, Abdollah Safari, Mark Harrison, Judy Illes
Abstract
The preferences of clinicians are drive primarily by the likelihood of achieving seizure freedom for their patients, but preferences for an intervention are largely eradicated if only low quality of evidence supporting the intervention is available. Until better evidence supporting the use of potentially effective, novel neurotechnologies becomes available, clinicians are likely to prefer more established treatments.
Related Papers
- → VNS in drug resistant epilepsy: preliminary report on a small group of patients(2010)12 cited
- [Vagus nerve stimulation (VNS) in the treatment of drug-resistant epilepsy. A 4-year follow-up evaluation of VNS treatment efficacy].(2004)
- → Clinical investigation of vagus nerve stimulation for treatment of drug-resistant epilepsy(2012)
- → Efficacy of VNS for Drug-Resistant Epilepsy in Structural Brain Lesions(2020)
- Vagus nerve stimulation (VNS) is an adjunctive treatment in iraqi patients with drug resistant epilepsy(2021)